Bridging Studies in Preclinical Pharmaceutical Safety Assessment

Abstract Preclinical toxicology bridging studies are unique to the safety evaluation of pharmaceuticals. Simple parallel comparative toxicity studies are commonly performed to establish that the active pharmaceutical ingredient (API) and/or clinical product are pharmacokinetically and toxicologically equivalent. This article discusses various aspects of preclinical pharmaceutical safety assessment in drug development studies.